Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/174258
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rosas-Umbert, Miriam | - |
dc.contributor.author | Ruiz-Riol, Marta | - |
dc.contributor.author | Fernández, Marco A. | - |
dc.contributor.author | Marszalek, Marta | - |
dc.contributor.author | Coll, Pep | - |
dc.contributor.author | Manzardo, Christian | - |
dc.contributor.author | Cedeño, Samandhy | - |
dc.contributor.author | Miró Meda, José M. | - |
dc.contributor.author | Clotet, Bonaventura, 1953- | - |
dc.contributor.author | Hanke, Tomás | - |
dc.contributor.author | Moltó, José | - |
dc.contributor.author | Mothe, Beatriz | - |
dc.contributor.author | Brander, Christian | - |
dc.date.accessioned | 2021-02-24T16:23:19Z | - |
dc.date.available | 2021-02-24T16:23:19Z | - |
dc.date.issued | 2020-03-20 | - |
dc.identifier.issn | 1664-3224 | - |
dc.identifier.uri | http://hdl.handle.net/2445/174258 | - |
dc.description.abstract | Romidepsin (RMD) is a well-characterized histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma. in vitro and in vivo studies have demonstrated that it is able to induce HIV-1 gene expression in latently infected CD4+ T cells from HIV-1+ individuals on suppressive antiretroviral therapy. However, in vitro experiments suggested that RMD could also impair T-cell functionality, particularly of activated T cells. Thus, the usefulness of RMD in HIV-1 kick&kill strategies, that aim to enhance the immune system elimination of infected cells after inducing HIV-1 viral reactivation, may be limited. In order to address whether the in vitro observations are replicated in vivo, we determined the effects of RMD on the total and HIV-1-specific T-cell populations in longitudinal samples from the BCN02 kick&kill clinical trial (NCT02616874). BCN02 was a proof-of-concept study in 15 early treated HIV-1+ individuals that combined MVA.HIVconsv vaccination with three weekly infusions of RMD given as a latency reversing agent. Our results show that RMD induced a transient increase in the frequency of apoptotic T cells and an enhanced activation of vaccine-induced T cells. Although RMD reduced the number of vaccine-elicited T cells secreting multiple cytokines, viral suppressive capacity of CD8+ T cells was preserved over the RMD treatment. These observations have important implications for the design of effective kick&kill strategies for the HIV-1 cure. | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Frontiers Media | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2020.00418 | - |
dc.relation.ispartof | Frontiers in Immunology, 2020, vol. 11, num. 418 | - |
dc.relation.uri | https://doi.org/10.3389/fimmu.2020.00418 | - |
dc.rights | cc-by (c) Rosas-Umbert, Miriam et al., 2020 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Cèl·lules T | - |
dc.subject.classification | Vacunació | - |
dc.subject.classification | Apoptosi | - |
dc.subject.other | T cells | - |
dc.subject.other | Vaccination | - |
dc.subject.other | Apoptosis | - |
dc.title | In vivo effects of romidepsin on T-Cell activation, apoptosis and function in the BCN02 HIV-1 kick&Kill clinical trial | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 701138 | - |
dc.date.updated | 2021-02-24T16:23:20Z | - |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/681137/EU//EAVI2020 | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 32265913 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
701138.pdf | 1.13 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License